Zentalis Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview

Zentalis Pharmaceuticals

31/07/2026 12:03

Zentalis Pharmaceuticals Inc ZNTL.OQ ZNTL.O is expected to  show no change in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Zentalis Pharmaceuticals Inc is for a loss of 49 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $7.00, about 42.3% above its last closing price of $4.92
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.49
-0.48
-0.50
Missed
-4.9
Dec. 31 2026
-1.80
-0.58
-0.50
Beat
13.6
Sep. 30 2025
-0.53
-0.53
-0.37
Beat
29.9​
Jun. 30 2025
-0.56
-0.58
-0.37
Beat
36.4
​​Mar. 31 2025
-0.65
-0.64
-0.56
Beat
12.2
Dec. 31 2024
-0.62
-0.71
-0.62
Beat
12.2​
Sep. 30 2024
-0.88
-0.91
-0.56
Beat
38.5
Jun. 30 2024
-0.87
-0.84
-1.24
Missed
-47.5
This summary was machine generated July 31 at 11:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)